TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the successful first in human implantation of its Topaz transfemoral tricuspid heart valve replacement system (“Topaz”) in Germany.

Click here to read the press release

Share on :

More news